Acorda Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2012 Financial Results on February 13, 2013
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will
host a conference call and live webcast to report its fourth quarter and
full year 2012 financial results on Wednesday, February 13 at 8:30 a.m.
ET.
To participate in the conference call, please dial 866-356-3095
(domestic) or 617-597-5391 (international) and reference the access code
66159419. The presentation will be available via a live webcast on the
Investors section of www.acorda.com.
Please log in approximately 5 minutes before the scheduled time of the
presentation to ensure a timely connection.
A replay of the call will be available from 10:30 a.m. ET on February
13, 2013 until midnight on March 13, 2013. To access the replay, please
dial 888-286-8010 (domestic) or 617-801-6888 (international) and
reference the access code 55654711. An archived version of the webcast
will be available for 30 days in the Investor Relations section of the
Acorda website at www.acorda.com.
About Acorda
Therapeutics
Acorda Therapeutics is a biotechnology company focused on developing
therapies that restore function and improve the lives of people with MS,
spinal cord injury and other neurological conditions.
Acorda markets AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg, in the United
States as a treatment to improve walking in patients with multiple
sclerosis (MS). This was demonstrated by an improvement in walking
speed. AMPYRA is marketed outside the United States as FAMPYRA®
(prolonged-release fampridine tablets) by Biogen Idec under a licensing
agreement from Acorda. AMPYRA and FAMPYRA are manufactured under license
from Alkermes Pharma Ireland Limited.
The Company also markets ZANAFLEX
CAPSULES® (tizanidine hydrochloride) and Zanaflex
tablets, a short-acting drug for the management of spasticity. Acorda
also receives sales royalties on tizanidine hydrochloride capsules, an
authorized generic version of ZANAFLEX CAPSULES distributed by Watson
Pharmaceutics, Inc. under its agreement with Acorda.
Acorda has an industry-leading pipeline of novel neurological therapies.
The Company is developing Diazepam Nasal Spray for treatment of certain
epileptic seizures. It is also studying AMPYRA to improve a range of
functional impairments caused by MS, as well as its potential for use in
other neurological conditions, including cerebral palsy and post-stroke
deficits. In addition, Acorda is developing clinical stage compounds
AC105 for acute treatment of spinal cord injury, GGF2 for treatment of
heart failure and rHIgM22, a remyelinating monoclonal antibody, for the
treatment of MS. GGF2 is also being investigated in preclinical studies
as a treatment for neurological conditions such as stroke and spinal
cord injury. Chondroitinase, an enzyme that encourages nerve plasticity
in spinal cord injury, is in preclinical development.
Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should be
considered forward-looking. These statements are subject to risks and
uncertainties that could cause actual results to differ materially,
including our ability to successfully market and sell Ampyra in the
U.S.; third party payers (including governmental agencies) may not
reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization
requirements that limit or block prescriptions; the risk of unfavorable
results from future studies of Ampyra or from our other research and
development programs, including Diazepam Nasal Spray (“DZNS”) or any
other acquired or in-licensed programs; we may not be able to complete
development of, obtain regulatory approval for, or successfully market
DZNS or other products under development; the occurrence of adverse
safety events with our products; delays in obtaining or failure to
obtain regulatory approval of or to successfully market Fampyra outside
of the U.S. and our dependence on our collaboration partner Biogen
Idec in connection therewith; competition, including the impact of
generic competition on Zanaflex Capsules revenues; failure to protect
our intellectual property, to defend against the intellectual property
claims of others or to obtain third party intellectual property licenses
needed for the commercialization of our products; failure to comply with
regulatory requirements could result in adverse action by regulatory
agencies; and the ability to obtain additional financing to support our
operations. These and other risks are described in greater detail
in Acorda Therapeutics' filings with the Securities & Exchange
Commission. Acorda may not actually achieve the goals or plans described
in its forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in this
release are made only as of the date hereof, and Acorda disclaims any
intent or obligation to update any forward-looking statements as a
result of developments occurring after the date of this release.
